{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"21.1","value":"13.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"This endpoint was analyzed using all patients treated at the MTD (Dose Level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day). This includes the eligible Phase I participants treated at Dose Level 1 (N=5) and it includes all participants treated in Phase II (N=77).","id":"OG000","title":"Sorafenib 200 mg Twice Daily, RAD001 5mg Every Day"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years from registration","title":"Survival Time","type":"SECONDARY","unitOfMeasure":"months"}